Bbva Compass Bancshares Inc. Has $8.47 Million Stake in Amgen, Inc. (AMGN)

Share on StockTwits

Bbva Compass Bancshares Inc. cut its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 6.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 43,484 shares of the medical research company’s stock after selling 2,938 shares during the quarter. Bbva Compass Bancshares Inc.’s holdings in Amgen were worth $8,466,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of AMGN. City Holding Co. increased its holdings in Amgen by 0.3% in the 4th quarter. City Holding Co. now owns 18,015 shares of the medical research company’s stock worth $3,506,000 after buying an additional 50 shares in the last quarter. Miracle Mile Advisors LLC increased its holdings in Amgen by 2.6% in the 4th quarter. Miracle Mile Advisors LLC now owns 1,992 shares of the medical research company’s stock worth $388,000 after buying an additional 50 shares in the last quarter. Livingston Group Asset Management CO operating as Southport Capital Management increased its holdings in Amgen by 1.8% in the 4th quarter. Livingston Group Asset Management CO operating as Southport Capital Management now owns 3,321 shares of the medical research company’s stock worth $646,000 after buying an additional 58 shares in the last quarter. Hudson Capital Management LLC increased its holdings in Amgen by 0.7% in the 4th quarter. Hudson Capital Management LLC now owns 8,192 shares of the medical research company’s stock worth $1,595,000 after buying an additional 59 shares in the last quarter. Finally, Deane Retirement Strategies Inc. increased its holdings in Amgen by 0.6% in the 4th quarter. Deane Retirement Strategies Inc. now owns 9,838 shares of the medical research company’s stock worth $1,915,000 after buying an additional 60 shares in the last quarter. Hedge funds and other institutional investors own 77.96% of the company’s stock.

In other news, Director Ronald D. Sugar sold 2,000 shares of Amgen stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $188.88, for a total transaction of $377,760.00. Following the transaction, the director now directly owns 14,988 shares of the company’s stock, valued at approximately $2,830,933.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.27% of the stock is owned by insiders.

Shares of NASDAQ:AMGN opened at $191.89 on Friday. The stock has a market capitalization of $119.58 billion, a price-to-earnings ratio of 13.33, a PEG ratio of 2.34 and a beta of 1.21. The company has a debt-to-equity ratio of 2.36, a quick ratio of 2.57 and a current ratio of 2.79. Amgen, Inc. has a 52-week low of $163.31 and a 52-week high of $210.19.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, January 29th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.26 by $0.16. Amgen had a return on equity of 66.74% and a net margin of 35.35%. The business had revenue of $6.23 billion for the quarter, compared to analysts’ expectations of $5.88 billion. During the same period last year, the firm posted $2.89 earnings per share. As a group, equities analysts anticipate that Amgen, Inc. will post 13.97 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be given a dividend of $1.45 per share. The ex-dividend date is Thursday, May 16th. This represents a $5.80 dividend on an annualized basis and a dividend yield of 3.02%. Amgen’s payout ratio is currently 40.28%.

Several equities research analysts recently commented on the company. Goldman Sachs Group reiterated a “buy” rating and issued a $232.00 price objective on shares of Amgen in a report on Tuesday, December 4th. Barclays reiterated a “neutral” rating and issued a $195.00 price objective on shares of Amgen in a report on Tuesday, December 4th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $223.00 price objective on shares of Amgen in a report on Tuesday, December 4th. JPMorgan Chase & Co. set a $192.00 target price on Amgen and gave the stock a “neutral” rating in a research report on Tuesday, December 4th. Finally, Royal Bank of Canada reissued a “neutral” rating and issued a $182.00 target price on shares of Amgen in a research report on Tuesday, December 4th. Twelve equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $209.79.

COPYRIGHT VIOLATION NOTICE: “Bbva Compass Bancshares Inc. Has $8.47 Million Stake in Amgen, Inc. (AMGN)” was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.tickerreport.com/banking-finance/4239671/bbva-compass-bancshares-inc-has-8-47-million-stake-in-amgen-inc-amgn.html.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Featured Story: Stop Order

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

$2.80 Billion in Sales Expected for Royal Caribbean Cruises Ltd  This Quarter
$2.80 Billion in Sales Expected for Royal Caribbean Cruises Ltd This Quarter
Waves Community Token Trading 1.3% Higher  Over Last Week
Waves Community Token Trading 1.3% Higher Over Last Week
Telcoin Price Tops $0.0006 on Major Exchanges
Telcoin Price Tops $0.0006 on Major Exchanges
Crystal Clear  Market Capitalization Tops $26,650.00
Crystal Clear Market Capitalization Tops $26,650.00
SwissBorg  Market Cap Tops $5.04 Million
SwissBorg Market Cap Tops $5.04 Million
OAX Price Hits $0.23 on Major Exchanges
OAX Price Hits $0.23 on Major Exchanges


© 2006-2019 Ticker Report